Edition:
United States

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

52.10USD
2:32pm EDT
Change (% chg)

$0.41 (+0.79%)
Prev Close
$51.69
Open
$51.72
Day's High
$52.10
Day's Low
$51.59
Volume
208,916
Avg. Vol
905,959
52-wk High
$52.33
52-wk Low
$39.90

Latest Key Developments (Source: Significant Developments)

Baxter expects to generate free cash flow of about $1.75 bln in 2020
Monday, 9 May 2016 04:05pm EDT 

Baxter International Inc : Company provides financial outlook for 2018 and 2020 . Expects to grow sales 3 to 4 percent on a compounded annual basis at constant currency rates from 2016 through 2018 . Expects a 2018 adjusted operating margin of 14 to 15 percent and 2018 adjusted diluted earnings of $2.10 to $2.25 per share . Also expects free cash flow (operating cash flow less capital expenditures) of approximately $1.0 billion in 2018 . Expects sales to grow approximately 4 percent on a compounded annual basis at constant currency rates from 2016 to 2020 . Anticipates an adjusted operating margin of 17 to 18 percent and adjusted diluted earnings of $2.75 to $3.00 per share in 2020 .Expects to generate free cash flow of approximately $1.75 billion in 2020.  Full Article

Baxter International Inc raises quarterly dividend
Tuesday, 3 May 2016 08:30am EDT 

Baxter International Inc:Board of Directors has declared a 13 percent increase in the company's quarterly dividend rate, from the previous rate of $0.115 per Baxter common share to $0.13 per share.Dividend is payable on July 1, 2016 to stockholders of record as of June 3, 2016.  Full Article

Baxter International Inc raises FY 2016 outlook; gives Q2 2016 outlook
Tuesday, 26 Apr 2016 07:00am EDT 

Baxter International Inc:Says that based on the company's strong first quarter performance, Baxter is raising its financial outlook for FY 2016.Expects constant currency sales growth for FY 2016 of about 3 percent, or about 4 percent after adjusting for increased U.S. competition for cyclophosphamide.Says that on a reported basis, including impact of foreign exchange, Baxter now expects sales to increase about 1 percent as compared to previous guidance of a decline of about 1 percent.Expects earnings from continuing operations, before special items, of $1.59 to $1.67 per diluted share for FY 2016 as compared to previous guidance of $1.46 to $1.54 per diluted share.Expects Q2 2016 constant currency sales growth of about 4 percent, and on a reported basis, sales growth of about 2 percent.Expects earnings from continuing operations, before special items, of $0.38 to $0.40 per diluted share for Q2 2016.Says earnings guidance for Q2 and FY 2016 excludes about $1.94 and $8.01, respectively, per diluted share of realized gains related to the planned use of the Baxalta retained stake.  Full Article

Baxter declares regular quarterly dividend of $0.115 per common share
Tuesday, 16 Feb 2016 08:25am EST 

Baxter International Inc:Declared a regular quarterly dividend of $0.115 per Baxter common share.  Full Article

Baxter International Inc gives FY, Q1 2016 guidance
Tuesday, 2 Feb 2016 07:00am EST 

Baxter International Inc:Expects FY 2016 sales to increase 2 to 3 percent excluding the impact of foreign exchange, and after adjusting for the impact of both foreign exchange and increased U.S. competition for cyclophosphamide, the company expects full-year sales growth of 3 to 4 percent.Says that on a reported basis, including the impact of foreign exchange, Baxter expects sales to decline about 1 percent.Expects earnings from continuing operations, before special items, of $1.46 to $1.54 per diluted share for FY 2016.Expects Q1 2016 expects sales to grow 3 to 4 percent, on a constant currency basisSays.On reported basis, including impact of foreign exchange, the company expects sales to decline about 2 percent.Expects earnings from continuing operations, before special items, of $0.28 to $0.30 per diluted share for Q1 2016.  Full Article

Baxter International Inc - Baxter Initiates Voluntary Nationwide Recall of Select Lots of IV Solutions Due to the Potential for Leaking Containers and Particulate Matter - ENPNWS
Monday, 25 Jan 2016 07:15am EST 

Baxter International Inc:Baxter International Inc. announced today it is voluntarily recalling four lots of intravenous (IV) solutions to the hospital/user level due to the potential for leaking containers and particulate matter. - ENPNWS.Baxter was made aware of these issues as the result of two complaints for leaking containers and one customer complaint each for three lots due to particulate matter. - ENPNWS.In each case, the issue was discovered prior to patient administration and there have been no adverse events associated with these incidents reported to Baxter to date. - ENPNWS.Leaking containers could result in contamination of the solution. If not detected, this could lead to a bloodstream infection, worsened patient condition or other serious adverse health consequences. - ENPNWS.Injecting a product containing particulate matter, in the absence of in-line filtration, may result in blockage of blood vessels, which can result in stroke, heart attack, damage to other organs such as the kidney or liver, or death. - ENPNWS.There is also the possibility of allergic reactions, local irritation and inflammation in tissues and organs. - ENPNWS.  Full Article

Baxter International Inc - Recalls continue to dog Baxter - CHITRI
Thursday, 7 Jan 2016 06:16am EST 

Baxter International Inc:Baxter International, the Deerfield-based maker of hospital and renal products, continued to be dogged with product-quality issues in 2015 as it issued at least five recalls on products from IV solutions to vascular patches - RTRS.Contaminated hospital supplies can be life-threatening, resulting in strokes, heart attacks and organ damage. - RTRS.A string of recalls could raise questions about a supplier's manufacturing and quality-control safeguards - RTRS.In the wake of the recalls, a new CEO, Jose Almeida, took the helm at Baxter this week, with a mission to rebuild the 84-year-old company. - RTRS.Baxter is dealing with the challenge of mature product lines and a slow-growing revenue base after the spinoff last summer of its pharmaceutical operations into the newly formed Baxalta Inc - RTRS.For Baxter, recalls are an ongoing issue. - RTRS.The Food and Drug Administration website shows numerous recalls each year for the past several years, with some that cost the company millions of dollars. - RTRS.  Full Article

Baxter International Inc declares quarterly dividend
Tuesday, 10 Nov 2015 08:55am EST 

Baxter International Inc:Declared a regular quarterly dividend of $0.115 per Baxter common share.Payable on January 4, 2016 to shareholders of record date as of December 4.  Full Article

Baxter International names new chairman and chief executive officer
Wednesday, 28 Oct 2015 04:45pm EDT 

Baxter International Inc:Has named José (Joe) Almeida the company's Chairman and Chief Executive Officer (CEO), effective Jan. 1, 2016.Almeida will join the company immediately as an executive officer to facilitate a smooth leadership transition.Almeida, 53, will succeed Robert L. Parkinson, Jr., who has served as the company's Chairman and CEO since 2004 and will retire from these roles Jan. 1, 2016, with a brief transition period thereafter.Upon retirement, Parkinson will assume the title of Chairman Emeritus.  Full Article

Baxter International Inc to cut 1,400 jobs worldwide to boost profits - Reuters
Tuesday, 27 Oct 2015 12:42pm EDT 

Baxter International Inc:Baxter International Inc said on Tuesday it plans to cut about 1,400 jobs worldwide, or about 5 percent of its non-manufacturing workforce, as part of a broad effort to reduce costs and boost profits - RTRS.About two-thirds of the job cuts are planned for outside the United States, with the lay-offs to be completed by the end of the year, Chief Executive Bob Parkinson said on the company's third-quarter earnings call - RTRS.The reduction is expected to save about $130 million a year, he said - RTRS.  Full Article

More From Around the Web

BRIEF-Baxter CEO José Almeida's FY 2016 compensation $5.8 mln vs $7.95 mln in FY 2015

* Ceo josé almeida's fy 2016 total compensation $5.8 million versus $7.95 million in fy 2015 - sec filing Source text for Eikon: Further company coverage: